Trillium Therapeutics

Developing innovative therapies for the treatment of cancer

Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-621 and TTI-622, target CD47, a “do not eat” signal that cancer cells frequently use to evade the immune system.

Status
NASDAQ: TRIL
Year of Investment
2020
Strategy
Life Sciences
Location
Cambridge, Massachusetts